BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20150369)

  • 1. Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
    Kato Y; Holm DA; Okollie B; Artemov D
    Neuro Oncol; 2010 Jan; 12(1):71-9. PubMed ID: 20150369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide.
    Kato Y; Okollie B; Artemov D
    Magn Reson Med; 2006 Apr; 55(4):755-61. PubMed ID: 16508914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
    Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
    Cao Y; Tsien CI; Shen Z; Tatro DS; Ten Haken R; Kessler ML; Chenevert TL; Lawrence TS
    J Clin Oncol; 2005 Jun; 23(18):4127-36. PubMed ID: 15961760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
    Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
    NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
    Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
    PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
    Zhou Q; Gallo JM
    Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits.
    Beccaria K; Canney M; Goldwirt L; Fernandez C; Piquet J; Perier MC; Lafon C; Chapelon JY; Carpentier A
    J Neurosurg; 2016 Jun; 124(6):1602-10. PubMed ID: 26566207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
    Liu HL; Huang CY; Chen JY; Wang HY; Chen PY; Wei KC
    PLoS One; 2014; 9(12):e114311. PubMed ID: 25490097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal temozolomide drug delivery using convection enhanced delivery.
    Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
    J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
    Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
    Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
    Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
    Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
    Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
    League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE
    J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
    Sharma AK; Gupta L; Sahu H; Qayum A; Singh SK; Nakhate KT; Ajazuddin ; Gupta U
    Pharm Res; 2018 Jan; 35(1):9. PubMed ID: 29294212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.